Baird analyst Brian Skorney reiterated an Outperform rating and $126 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Gilead Sciences (GILD) 'Crushed' the Quarter, Piper Jaffray Says; Remains Top Large-Cap Biotech PickMay 1, 2015 7:10 AM Gilead Sciences (GILD) Bullish Stance Reiterated at BMO Capital Amid 'Strong' Q1May 1, 2015 7:00 AM Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue GuidanceApril 30, 2015 4:02 PM Gilead Sciences Announces First Quarter 2015 Financial ResultsApril 30, 2015 4:02 PM